MK386: A potent, selective inhibitor of the human type 1 5α-reductase

Journal of Steroid Biochemistry and Molecular Biology

Volumn 58, Issue 4, 1996, Pages 377-384

  Ellsworth, K ^a   Azzolina, B ^a   Baginsky, W ^a   Bull, H ^a   Chang, B ^a   Cimis, G ^a   Mitra, S ^a   Toney, J ^a   Bakshi, R K ^a   Rasmusson, G R ^a   Tolman, R L ^a   Harris, G S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AROMATASE; ISOENZYME; RECOMBINANT PROTEIN; STEROID 5ALPHA REDUCTASE INHIBITOR; STEROID 5BETA REDUCTASE; TESTOSTERONE 17BETA DEHYDROGENASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MEMBRANE BINDING; PROSTATE; SEBACEOUS GLAND;

EID: 0030200204     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(96)00050-7     Document Type: Article

References (27)

1. 1. Metcalf B. W., Levy M. A. and Holt D. A.: Inhibitors of 5α-reductase in benign prostatic hyperplasia, male pattern baldness and acne. Trends Pharmac. Sci. 10 (1989) 491-495.
2. 2. Li X., Chem C., Singh S. M. and Labrie F.: The enzyme and inhibitors of 4-ene-3-oxosteroid 5α-reductase. Steroids 60 (1995) 430-441.
3. 3. Brooks J. R., Harris, G. S. and Rasmusson G. R.: Inhibitors of steroid 5α-reductase. In Design of Enzyme Inhibitors as Drugs (Edited by M. Samdler and H. J. Smith). Oxford University Press, Oxford (1994) pp. 495-518.
4. 4. Thigpen A. E., Silver R. I., Guileyardo J. M., Casey M. L., McConnell J. D. and Russell D. W.: Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J. Clin. Invest. 92 (1993) 903-910.
5. 5. Harris G., Azzolina B., Baginsky W., Cimis G., Rasmusson G. H., Tolman R. L., Raetz C. R. H. and Ellsworth K.: Identification and selective inhibition of an isozyme of steroid 5α-reductase in human scalp. Proc. Natn. Acad. Sci. U.S.A. 89 (1992) 10787-10791.
6. 6. Jones C. D., Audia J. E., Lawhorn D. E., McQuaid L. A., Neubauer R. L., Pike A. J., Pennington P. A., Stamm N. B., Toomey R. E. and Hirsch K. S.: Nonsteroidal inhibitors of human type 1 5α-reductase. J. Med. Chem. 36 (1993) 421-423.
7. 7. Hirsch K. S., Jones C. D. A. J. E., Andersson S., McQuaid L., Stamm N. B., Neubauer B. I., Pennington P. and Toomey R. E.: LY191704: a selective, nonsteroidal inhibitor of human steroid 5α-reductase type 1. Proc. Natn. Acad. Sci. U.S.A. 90 (1993) 5277-5281.
8. 8. Bakshi R. K., Patel G. F., Rasmusson G. H., Baginsky W. F., Cimis G., Ellsworth K., Chang B., Bull H., Tolman T. L. and Harris G. S.: 4,7β-Dimethyl-4-azacholestan-3-one (MK386) and related 4-azasteroids as selective inhibitors of human type 1 5α-reductase. J. Med. Chem. 37 (1994) 3871-3874.
9. 9. Schwartz J., Van Hecken A., De L. I., Wang D., Depre M., De Schepper P. and Gertz B.: Pharmacodynamics of MK386 - A novel inhibitor of 5α-reductase. Clin. Pharmacol. Ther. 57 (1995) 171.
10. 10. Gormley G. J., Stoner E., Rittmaster R. S., Gregg H., Thompson D. L., Lasseter K. G., Vlasses P. H. and Stein E. A.: Effects of finasteride (MK906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J. Clin. Endocr. Metab. 70 (1990) 1136-1141.
11. 11. Audet P., Nurcombe H., Lamb Y., Jorasky D., Lloyd-Davis K. and Morris X. X.: Effect of multiple doses of epristeride (E) a steroid 5α-reductase inhibitor on serum dihydrotestosterone in older male subjects. Clin. Pharmacol. Ther. 53 (1993) 231-233.
12. 12. McConnell J. D., Wilson J. D., George F. W., Geller J., Pappas F. and Stoner E.: Finasteride, an inhibitor of 5α-reductase suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J. Clin. Endocr. Metab. 74 (1992) 505-508.
13. 13. Thiboutot D., Harris G., Iles V., Cimis G., Gilliland K. and Hagari S.: Activity of the type 1 5α-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J. Invest. Dermatol. 105 (1995) 209-214.
14. 14. Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275.
15. 15. Chan H. K., Geissler W. M. and Andersson S.: Characterization of human steroid 5α-reductase type 1 and 2 expressed in the baculovirus system. In Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects (Edited by M. Motta and M. Serio). Elsevier Science M.V., Amsterdam (1994), pp. 67-76.
16. 16. Morrison J. F. and Walsh C. T.: The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Molec. Biol. 61 (1988) 201-301.
17. 17. Tilley W. D., Marcelli M., Wilson J. D. and McPhaul M. J.: Characterization and expression of a cDNA encoding the human androgen receptor. Proc. Natn. Acad. Sci. U.S.A. 86 (1989) 327-331.
18. 18. Tian G., Stuart J. D., Moss M. L., Domanico P. L., Bramson H. N., Patel I. R., Kadwell S. H., Overton L. K., Kost T. A., Mook Jr, R. A., Frye S. V., Batchelor K. W. and Wiseman J. S.: 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androstan-1-en-3-one is an active site directed slow time-dependent inhibitor of human steroid 5α-reductase 1. Biochem. 33 (1994) 2281-2296.
19. 19. Faller B., Farley D. and Nick H.: Finasteride: A slow-binding 5α-reductase inhibitor. Biochemistry 32 (1993) 5705-5710.
20. 20. Baginsky W. F., Harris G. and Bull H.: Mechanism of inhibition of human prostatic 5α-reductase by 4-azasteroids. FASEB J. 8 (1994) A638.
21. 21. Liang T. and Heiss C. E.: Inhibition of 5α-reductase, receptor binding and nuclear uptake of androgens in the prostate by a 4-methyl-4-aza-steroid. J. Biol. Chem. 256 (1981) 7998-8005.
22. 5-steroid isomerase from bovine adrenals: Mechanism of inhibition by 3-oxo-4-azasteroids and kinetic mechanism of the dehydrogenase. Biochemistry 28 (1989) 140-148.
23. 23. Yanaihara T. and Troen P.: Studies of the human testis. 1. Biosynthetic pathways for androgen formation in human testicular tissue in vitro. J. Clin. Endocr. Metab. 34 (1972) 783-792.
24. 24. Arth G. E., Patchett A. A., Jefopoulus T., Bugianesi R. L. and Peterson L. H.: Steroidal androgen biosynthesis inhibitors. J. Med. Chem. 14 (1971) 675-679.
25. 25. Casey M. L., MacDonald P. C. and Andersson S.: 17β-hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium. J. Clin. Invest. 94 (1994) 2135-2141.
26. 26. Rasmusson G., Reynolds G., Steinberg N., Walton E., Patel G., Liang T., Cascieri M., Cheung A., Brooks J. and Berman C.: Azasteroids: structure-activity relationships for inhibition of 5α-reductase and of androgen receptor binding. J. Med. Chem. 29 (1986) 2298-2315.
27. 27. Summerfield A. E., Diaz Cruz P. J., Dolenga M. P., Smith H. E., Strader C. and Toney J. H.: Tissue-specific pharmacology of testosterone and 5α-dihydrotestosterone analogues: characterization of a novel canine liver androgen binding protein. Molec. Pharmacol. 47 (1995) 1080-1088.